Impact of fibre and red/processed meat intake on treatment outcomes among patients with chronic inflammatory diseases initiating biological therapy: A prospective cohort study
Overgaard SH, Sørensen SB, Munk HL, Nexøe AB, Glerup H, Henriksen RH, Guldmann T, Pedersen N, Saboori S, Hvid L, Dahlerup JF, Hvas CL, Jawhara M, Andersen KW, Pedersen AK, Nielsen OH, Bergenheim F, Brodersen JB, Heitmann BL, Halldorsson TI, Holmskov U, Bygum A, Christensen R, Kjeldsen J, Ellingsen T, Andersen V
Frontiers in nutrition · 16 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Cohort study (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
- Intake measured by
- Food frequency questionnaire
Who paid for it
- Funding
- Independent funding
- Nonprofit
- Oak Foundation
- Nonprofit
- Parker Institute for Cancer Immunotherapy
- Government
- European Commission
- University or hospital
- Odense Universitetshospital
- Nonprofit
- Knud og Edith Eriksens Mindefond
- Government
- Horizon 2020
- Authors
- At least one author declares a financial tie to industry
- Grants
- Parker Institute for Cancer Immunotherapy (OCAY-18-774-OFIL); European Commission (HORIZON2020); European Commission (733100)
Based on 6 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2022-10-13 · Front Nutr · vol. 9 · p. 985732
- Publisher
- Frontiers Media
- Cited
- 17 citations · more than 90% of similar papers · 2.4× the field average
- References
- 55 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Inflammatory Bowel Disease · Gut microbiota and health · Rheumatoid Arthritis Research and Therapies
- Keywords
- Medicine, Prospective cohort study, Cohort, Cohort study, Internal medicine, Intensive care medicine
26 authors
From DK, IS
- Silja Hvid Overgaard · correspondingUniversity of Southern Denmark; Frederiksberg Hospital
- Signe Bek SørensenUniversity of Southern Denmark
- Heidi Lausten MunkUniversity of Southern Denmark; Odense University Hospital
- Anders Bathum NexøeUniversity of Southern Denmark; Odense University Hospital
- Henning GlerupRegionshospitalet Silkeborg
- Rikke Holm HenriksenRegionshospitalet Silkeborg
Abstract
Background
Biologic disease-modifying drugs have revolutionised the treatment of a number of chronic inflammatory diseases (CID). However, up to 60% of the patients do not have a sufficient response to treatment and there is a need for optimization of treatment strategies.
Objective
To investigate if the treatment outcome of biological therapy is associated with the habitual dietary intake of fibre and red/processed meat in patients with a CID.
Methods
In this multicentre prospective cohort study, we consecutively enrolled 233 adult patients with a diagnosis of Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis (RA), Axial Spondyloarthritis, Psoriatic Arthritis and Psoriasis, for whom biologic therapy was planned, over a 3 year period. Patients with completed baseline food frequency questionnaires were stratified into a high fibre/low red and processed meat exposed group (HFLM) and an unexposed group (low fibre/high red and processed meat intake = LFHM). The primary outcome was the proportion of patients with a clinical response to biologic therapy after 14-16 weeks of treatment.
Results
Of the 193 patients included in our primary analysis, 114 (59%) had a clinical response to biologic therapy. In the HFLM group (N = 64), 41 (64%) patients responded to treatment compared to 73 (56%) in the LFHM group (N = 129), but the difference was not statistically significant (OR: 1.48, 0.72-3.05). For RA patients however, HFLM diet was associated with a more likely clinical response (82% vs. 35%; OR: 9.84, 1.35-71.56).
Conclusion
Habitual HFLM intake did not affect the clinical response to biological treatment across CIDs. HFLM diet in RA patients might be associated with better odds for responding to biological treatment, but this would need confirmation in a randomised trial.
Trial registration
(clinicaltrials.gov), identifier [NCT03173144].
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.